Implementation of a two-group likelihood time-to-event continual reassessment method using SAS

被引:8
作者
Salter, Amber [1 ]
Morgan, Charity [1 ]
Aban, Inmaculada B. [1 ]
机构
[1] Univ Alabama Birmingham, Sch Publ Hlth, Dept Biostat, Birmingham, AL 35294 USA
关键词
Adaptive designs; Phase I trial; Dose finding; Continual reassessment method; Maximum likelihood; Sample size; I CLINICAL-TRIALS; DESIGN; ONSET; MODEL;
D O I
10.1016/j.cmpb.2015.06.001
中图分类号
TP39 [计算机的应用];
学科分类号
081203 ; 0835 ;
摘要
Background and objectives: Dose finding trials using model-based methods have the ability to handle the increasingly complex landscape being seen in clinical trials. Issues such as patient heterogeneity in trial populations are important to address in the designing of a trial in addition to the inclusion/exclusion criteria. Designs accommodating patient heterogeneity have been described using the continual reassessment method (CRM) and time-to-event CRM (TITE-CRM), yet, the implementation of these trials in practice have been limited. These methods and other model-based methods generally need statisticians to help design and conduct these trials. However, the statistical programs which facilitate the use of these methods, currently available focus on estimation in the one-sample case. Methods: A SAS program to accommodate two groups using the TITE-CRM and likelihood estimation has been developed. The program consists of macros that assist with the planning and implementation of a trial accounting for patient heterogeneity. Results: Description of the program is given as well as examples using the programs. For planning purposes, an example will be provided showing how the program can be used to guide sample size estimates for the trial. Conclusions: This program provides researchers with a valuable tool for designing dose finding studies to account for the presence of patient heterogeneity and conduct a trial using a hypothetical example. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:189 / 196
页数:8
相关论文
共 25 条
[1]  
[Anonymous], ADV DOS ESC COMPL E
[2]  
[Anonymous], TITE CRM PHAS I CLIN
[3]  
[Anonymous], SOFTW DOWNL
[4]  
[Anonymous], BST2015001 U AL BIRM
[5]  
[Anonymous], DFCRM DOSE FINDIND C
[6]  
[Anonymous], CRM CONTINUAL REASSE
[7]  
[Anonymous], 2011, SAS STAT 9 3 USERS G
[8]  
[Anonymous], FIX AD CLIN TRIAL SI
[9]   Generalizing the TITE-CRM to adapt for early- and late-onset toxicities [J].
Braun, TM .
STATISTICS IN MEDICINE, 2006, 25 (12) :2071-2083
[10]  
Chang M., 2008, ADAPTIVE DESIGN THEO